Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia
- 1 February 2011
- journal article
- case report
- Published by Wiley in British Journal of Haematology
- Vol. 153 (1) , 43-46
Abstract
We have identified two novel ABL1 fusion genes in two patients with B-cell acute lymphoblastic leukaemia (ALL) associated with a t(3;9)(p12;q34) and a t(5;9)(q23;q34), respectively. Molecular analysis revealed a FOXP1-ABL1 fusion for the t(3;9) and a SNX2-ABL1 fusion for the t(5;9). The fusions were confirmed by specific amplification of the genomic breakpoints using reverse transcription polymerase chain reaction. The identification of ALL with rare ABL1 fusion partners is important because the leukaemia may respond to tyrosine kinase inhibitors in the same way as ALL patients with a classical BCR-ABL1 fusion gene.Keywords
This publication has 11 references indexed in Scilit:
- Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97Leukemia, 2009
- A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34)Haematologica, 2009
- Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemiaLeukemia, 2008
- Endosomal sorting and signalling: an emerging role for sorting nexinsNature Reviews Molecular Cell Biology, 2008
- Acute lymphoblastic leukaemiaThe Lancet, 2008
- The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre‐mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1Genes, Chromosomes and Cancer, 2008
- Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemiaThe Lancet Oncology, 2007
- Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinasesClinical Science, 2006
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid GeneScience, 1986